BrightFocus Foundation announces $7.2 million in grants for Alzheimer's and vision disease research

July 10, 2013

Clarksburg, MD--BrightFocus Foundation, a nonprofit organization that funds innovative, early-stage research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced grant awards totaling more than $7.2 million to 53 scientists in 16 states and four foreign countries.

The funded research projects reflect the full range of new tools and innovations--in imaging technology, gene therapy, and cell regeneration--that scientists are using to better understand how diseases of mind and sight develop. Study results could lead to new therapies to prevent or treat these diseases.

"Investment in research has advanced our understanding of Alzheimer's and vision diseases," said BrightFocus President and CEO, Stacy Pagos Haller. "Now, thanks to new developments in genetics, neurology and imaging, the potential for scientists to make groundbreaking research discoveries is taking off. BrightFocus Foundation is more committed than ever to making this cutting-edge research possible, particularly at a time when government research funding levels are stagnant."

BrightFocus has provided $130 million to date in research funding, awarding more than $26 million for research on diseases of mind and sight in the last four years alone. This year's grantees include researchers from across the U.S., as well as Australia, Great Britain, Ireland, and Israel.

Alzheimer's Disease Research

Alzheimer's is a devastating degenerative disease that irreversibly destroys memory and other brain function over time. BrightFocus-funded scientists are studying various ways in which the "memory pathways" in the brain--the systems by which brain cells communicate--can go awry in this disease.

Some researchers are investigating whether certain chemicals control the "switches" to these pathways; others are using highly refined brain imaging or magnetic brain stimulation techniques to learn more about pathways; and some are using cell-based therapies to try to restore the brain circuits made during memory formation. Still others are studying how problems with brain blood flow contribute to Alzheimer's disease.

Glaucoma Research

For all three diseases, scientists want to know how inflammation and the body's immune response system may be involved, making the body turn against healthy cells in the brain or eyes. Several glaucoma researchers are examining the mind-eye connection, and why changes in the brain may contribute to the development of glaucoma long before vision loss occurs. Early detection is particularly important for glaucoma: in the U.S., an estimated half of the three million people with glaucoma may not know they have the disease.

Macular Degeneration Research

New cell-based and gene-based therapies may help stop the nerve damage and the loss of the eye's retinal cells involved in macular degeneration. The latest cell regeneration techniques may allow scientists to restore damaged eye cells or generate new healthy ones. Researchers are also investigating the mysterious presence of micro RNAs, a large group of small molecules that may affect the functioning of the retina in macular degeneration--as well as brain functions in Alzheimer's disease.
-end-
ABOUT BRIGHTFOCUS FOUNDATION

BrightFocus Foundation (http://www.brightfocus.org), formerly the American Health Assistance Foundation, is a nonprofit organization dedicated to advancing brain and eye health, by funding research worldwide on Alzheimer's disease, macular degeneration, and glaucoma. BrightFocus also provides the public with information about these diseases, including risk factors, current treatments, and coping strategies. Read more about the new grant projects.

CONTACT:
Alice L. Kirkman
BrightFocus Marketing and Communications Manager
(301) 556-9349; akirkman@brightfocus.org

BrightFocus Foundation

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.